Peter C Yang
Overview
Explore the profile of Peter C Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rubinstein S, Sethi T, Venepalli N, Gyawali B, Schwartz C, Rivera D, et al.
JCO Clin Cancer Inform
. 2021 Jan;
5:30-35.
PMID: 33411619
Cancer medicine has grown increasingly complex in recent years with the advent of precision oncology and wide utilization of multidrug regimens. Representing this increasingly granular knowledge is a significant challenge....
2.
Li X, Sigworth E, Wu A, Behrens J, Etemad S, Nagpal S, et al.
Sci Rep
. 2020 Oct;
10(1):17536.
PMID: 33067482
Clinical trials establish the standard of cancer care, yet the evolution and characteristics of the social dynamics between the people conducting this work remain understudied. We performed a social network...
3.
Rubinstein S, Yang P, Cowan A, Warner J
JCO Clin Cancer Inform
. 2020 Jan;
4:60-70.
PMID: 31990580
Purpose: Due to decades of nonstandardized approaches to the naming of chemotherapy regimens, representation in electronic health records and secondary systems is highly variable. This hampers efforts to understand patterns...
4.
Warner J, Dymshyts D, Reich C, Gurley M, Hochheiser H, Moldwin Z, et al.
J Biomed Inform
. 2019 Jun;
96:103239.
PMID: 31238109
Systematic application of observational data to the understanding of impacts of cancer treatments requires detailed information models allowing meaningful comparisons between treatment regimens. Unfortunately, details of systemic therapies are scarce...
5.
Warner J, Yang P, Alterovitz G
JCO Clin Cancer Inform
. 2019 Jan;
1():1-9.
PMID: 30657401
Purpose: Despite the plethora of randomized controlled trial (RCT) data, most cancer treatment recommendations are formulated by experts. Alternatively, network meta-analysis (NMA) is one method of analyzing multiple indirect treatment...
6.
Malty A, Jain S, Yang P, Harvey K, Warner J
JCO Clin Cancer Inform
. 2018 Sep;
2.
PMID: 30238070
Purpose: The systemic treatment of cancer is primarily through the administration of complex chemotherapy protocols. To date, this knowledge has not been systematized, because of the lack of a consistent...
7.
Warner J, Cowan A, Hall A, Yang P
J Oncol Pract
. 2015 Mar;
11(3):e336-50.
PMID: 25736385
Purpose: Cancer care involves extensive knowledge about numerous chemotherapy drugs and chemotherapy regimens. This information is constantly evolving, and there has been no freely available, comprehensive, centralized repository of chemotherapy...
8.
Owens C, Song B, Perron M, Yang P, Stremlau M, Sodroski J
J Virol
. 2004 Apr;
78(10):5423-37.
PMID: 15113921
In cells of Old World and some New World monkeys, dominant factors restrict human immunodeficiency virus type 1 (HIV-1) infections after virus entry. The simian immunodeficiency virus SIV(mac) is less...
9.
Owens C, Yang P, Gottlinger H, Sodroski J
J Virol
. 2002 Dec;
77(1):726-31.
PMID: 12477877
The cells of most Old World monkey species exhibit early, postentry restrictions on infection by human immunodeficiency virus type 1 (HIV-1) but not by simian immunodeficiency virus of macaques (SIV(mac))....